Simvastatin for rats with thioacetamide-induced liver failure and encephalopathy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT2, 2008, Pages

  Huang, Hui Chun ^a,c   Wang, Sun Sang ^b,c   Lee, Fa Yauh ^a,c   Chan, Cho Yu ^a,c   Chang, Full Young ^a,c   Lin, Han Chieh ^a,c   Chu, Chi Jen ^a,c   Chen, Yi Chou ^a   Lee, Shou Dong ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

3 hydroxy methyl 3 glutamyl coenzyme A reductase inhibitors; Acute liver damage; Hepatic encephalopathy; Nitric oxide

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; N(G) NITROARGININE METHYL ESTER; SIMVASTATIN; SODIUM CHLORIDE; THIOACETAMIDE; WATER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HEPATIC ENCEPHALOPATHY; INJECTION; LIVER FAILURE; LIVER INJURY; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 47649110540     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04988.x     Document Type: Article

References (55)

1. Gammal SH, Hones EA. Hepatic encephalopathy. Med. Clin. North. Am. 1989 73 : 793 813.
2. Sherlock S. Fulminant hepatic failure. Adv. Intern. Med. 1993 38 : 245 67.
3. Mousseau DD, Butterworth RF. Current theories on the pathogenesis of hepatic encephalopathy. Soc. Exp. Biol. Med. 1994 206 : 329 44.
4. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994 20 : 1359 63.
5. Master S, Gottstein J, Blei AT. Cerebral blood flow and the development of ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 1999 30 : 876 80.
6. Cordoba J, Crespin J, Gottstein J, Blei AT. Mild hypothermia modifies ammonia-induced brain edema in rats after portacaval anastomosis. Gastroenterology 1999 116 : 686 93.
7. Aggarwal S, Kramer D, Yonas H et al. Cerebral hemodynamic and changes in fulminant hepatic failure: a retrospective study. Hepatology 1994 19 : 80 87.
8. Blei AT. Medical therapy of brain edema in fulminant hepatic failure. Hepatology 2000 32 : 666 98.
9. Palmer PMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from 1-arginine. Nature 1988 333 : 664 7.
10. Albrecht J, Hilgier W, Rafalowska U. Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptative response? J. Neurosci. Res. 1990 25 : 125 30.
11. 3H]nitroarginine into rat brain synaptosomes. J. Neurochem. 1997 68 : 337 43.
12. Mans AM, DeJoseph MR, Hawkins RA. Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. J. Neurochem. 1994 63 : 1829 38.
13. Albrecht J. Roles of neuroactive amino acids in ammonia neurotoxicity. J. Neurosci. Res. 1998 51 : 133 8.
14. Rao VL, Butterworth RF. Neuronal nitric oxide synthase and Hepatic Encephalopathy. Metab. Brain Dis. 1998 13 : 175 89.
15. Kosenko E, Kaminsky Y, Grau E, Misana MD, Grisolia S, Felipo V. Nitroarginine, an inhibitor of nitric oxide synthetase, attenuates ammonia toxicity and ammonia-induced alterations in brain metabolism. Neurochem. Res. 1995 20 : 451 6.
16. Chu CJ, Wang SS, Lee FY et al. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. Eur. J. Clin. Invest. 2001 31 : 156 63.
17. Bruck R, Aeed H, Shirin H et al. The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide- induced fulminant hepatic failure. J. Hepatol. 1999 31 : 27 38.
18. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 1988 62 : 10 15.
19. Laufs U, La Fata V, Plutzky J, Lial JM. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998 97 : 1129 35.
20. Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am. J. Physiol. 2002 283 : H768 75.
21. McGirt MJ, Lynch JR, Parra A et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002 33 : 2950 56.
22. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001 32 : 980 86.
23. Oberti F, Pilette C, Rifflet H et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J. Hepatol. 1997 26 : 1363 71.
24. Cai SR, Motoyama K, Shen KJ, Kennedy SC, Flye MW, Ponder KP. Lovastatin decreases mortality and improves liver functions in fulminant hepatic failure from 90% partial hepatectomy in rats. J. Hepatol. 2000 32 : 67 77.
25. Zafra C, Abraldes JG, Turnes J et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004 126 : 749 55.
26. Gammal S, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy benzodiazepine receptor ligands. Hepatology 1990 11 : 371 8.
27. Ribeiro J, Nordlinger B, Ballet F et al. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in portacaval-shunted rats. Hepatology 1992 15 : 12 18.
28. Conjeevaram HS, Nagle A, Katz A, Kaminsky-Russ K, McCullough AJ, Mullen KD. Reversal of behavior changes in rats subjected to portacaval shunt with oral neomycin therapy. Hepatology 1994 19 : 1245 50.
29. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997 28 : 946 50.
30. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996 335 : 1001 9.
31. Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke 2001 32 : 2185 91.
32. Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG) -CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 1998 95 : 8880 85.
33. Yamada M, Huang Z, Dalkara T et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J. Cereb. Blood Flow. Metab. 2000 20 : 709 17.
34. Pannen BH, Al-Adili F, Bauer M, Clemens MG, Geiger KK. Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology 1998 27 : 755 64.
35. Minnard EA, Shou J, Naama H, Cech A, Gallagher H, Daly JM. Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch. Surg. 1994 129 : 142 8.
36. Rahman TM, Hodgson HJ. The effects of early and late administration of inhibitors of inducible nitric oxide synthase in a thioacetamide-induced model of acute hepatic failure in the rat. J. Hepatol. 2003 38 : 583 90.
37. Lukivskaya O, Lis R, Zwierz K, Buko V. Effect of the nitric oxide donor and the nitric oxide synthase inhibitor on the liver of rats with chronic hepatitis induced by dimethylnitrosamine. Pol. J. Pharmacol. 2004 56 : 599 604.
38. Wang Y, Mathews WR, Guido DM, Farhood A, Jaeschke H. Inhibition of nitric oxide synthesis aggravates reperfusion injury after hepatic ischemia and endotoxemia. Shock 1995 4 : 282 8.
39. Vos TA, Gouw AS, Klok PA et al. Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 1997 113 : 1323 33.
40. Lee VG, Johnson ML, Baust J, Laubach VE, Watkins SC, Billiar TR. The roles of iNOS in liver ischemia-reperfusion injury. Shock 2001 16 : 355 60.
41. Kawachi S, Hines IN, Laroux FS et al. Nitric oxide synthase and postischemic liver injury. Biochem. Biophys. Res. Commun. 2000 276 : 851 4.
42. Rao VL, Audet RM, Butterworth RF. Increased nitric oxide synthase activities and L-[3H]arginine uptake in brain following portacaval anastomosis. J. Neurochem. 1995 65 : 677 8.
43. Nussler AK, Di Silvio M, Billiar TR et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J. Exp. Med. 1992 176 : 261 4.
44. Geller DA, de Vera ME, Russell DA et al. A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1 beta induces hepatic nitric oxide synthesis. J. Immunol. 1995 155 : 4890 98.
45. Huang HC, Wang SS, Chan CY et al. Role of hepatic nitric oxide synthases in rats with thioacetamide-induced acute liver failure and encephalopathy. J. Chin. Med. Assoc. 2006 70 : 16 23.
46. Coelho-Filho OR, De Luca IM, Tanus-Santos JE et al. Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats. Int. J. Cardiol. 2001 79 : 215 21.
47. Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch. Intern. Med. 2003 163 : 657 9.
48. Pfeffer MA, Keech A, Sacks FM et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002 105 : 2341 6.
49. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004 24 : 584 91.
50. Tolman KG. The liver and lovastatin. Am. J. Cardiol. 2002 89 : 1374 80.
51. Comporti M. Lipid peroxidation and cellular damage in toxic liver injury. Lab. Invest. 1985 53 : 599 623.
52. O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ. Res. 2001 88 : 12 21.
53. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 2000 20 : 61 9.
54. Rikitake Y, Kawashima S, Takeshita S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001 154 : 87 96.
55. Thakur NK, Hayashi T, Sumi D, Kano H, Tsunekawa T, Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am. J. Physiol. 2001 281 : H75 83.